Contrasting performance of the Swiss giants
02/12/20 -"Recently, there has been pertinent share price performance divergence between Novartis and Roche. While, for a long time, Novartis had the upper hand, it seems that Roche’s (rare) underperformance ..."
Pages
69
Language
English
Published on
02/12/20
You may also be interested by these reports :
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...
23/04/24
The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...